Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Dexcom (DXCM) Leases (2019 - 2025)

Dexcom (DXCM) has disclosed Leases for 11 consecutive years, with $77.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases rose 23.25% to $77.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $77.4 million, a 23.25% increase, with the full-year FY2025 number at $77.4 million, up 23.25% from a year prior.
  • Leases was $77.4 million for Q4 2025 at Dexcom, up from $54.0 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $98.8 million in Q1 2021 to a low of $54.0 million in Q3 2025.
  • A 5-year average of $75.1 million and a median of $74.8 million in 2023 define the central range for Leases.
  • Peak YoY movement for Leases: skyrocketed 33.88% in 2021, then dropped 20.79% in 2025.
  • Dexcom's Leases stood at $88.1 million in 2021, then fell by 9.19% to $80.0 million in 2022, then fell by 10.75% to $71.4 million in 2023, then decreased by 12.04% to $62.8 million in 2024, then grew by 23.25% to $77.4 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Leases are $77.4 million (Q4 2025), $54.0 million (Q3 2025), and $56.4 million (Q2 2025).